Boothbay Fund Management LLC Trims Stock Position in Cencora, Inc. (NYSE:COR)

Boothbay Fund Management LLC lowered its position in Cencora, Inc. (NYSE:COR - Free Report) by 95.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,359 shares of the company's stock after selling 30,065 shares during the quarter. Boothbay Fund Management LLC's holdings in Cencora were worth $305,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of COR. Price T Rowe Associates Inc. MD lifted its position in Cencora by 0.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company's stock valued at $1,990,542,000 after buying an additional 78,066 shares during the last quarter. Boston Partners lifted its holdings in shares of Cencora by 2.6% in the 4th quarter. Boston Partners now owns 5,007,100 shares of the company's stock worth $1,128,058,000 after acquiring an additional 125,611 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Cencora by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company's stock worth $969,471,000 after purchasing an additional 130,213 shares during the period. Invesco Ltd. increased its holdings in Cencora by 20.4% in the 4th quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock valued at $728,757,000 after purchasing an additional 550,246 shares during the last quarter. Finally, Pacer Advisors Inc. raised its position in Cencora by 6.7% in the fourth quarter. Pacer Advisors Inc. now owns 2,204,242 shares of the company's stock valued at $495,249,000 after purchasing an additional 138,868 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,223 shares of company stock worth $13,580,967. Company insiders own 10.80% of the company's stock.

Cencora Stock Down 0.3 %

NYSE COR traded down $0.85 on Tuesday, hitting $291.12. 1,364,057 shares of the stock were exchanged, compared to its average volume of 1,507,549. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65. The company has a 50-day moving average price of $273.47 and a 200-day moving average price of $252.02. The company has a market cap of $56.45 billion, a PE ratio of 41.41, a PEG ratio of 1.31 and a beta of 0.60. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.76%. Cencora's dividend payout ratio is presently 31.29%.

Analysts Set New Price Targets

COR has been the subject of a number of research reports. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Morgan Stanley set a $288.00 target price on Cencora in a research report on Tuesday, April 15th. Evercore ISI increased their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. UBS Group lifted their price objective on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Finally, JPMorgan Chase & Co. increased their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $290.00.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.